Comparison Chart Xilio Therapeutics, Inc.

Stocks

XLO

US98422T2096

Biotechnology & Medical Research

Market Closed - Nasdaq 20:00:00 30/10/2026 GMT			5-day change	1st Jan Change
8.030 ^USD	+3.35%		+6.08%	-10.41%

10-26	Xilio Therapeutics, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Xtx501 in Patients with Metastatic Nsclc	CI
09-28	Xilio Therapeutics, Inc. Announces Appointment of Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	XILIO THERAPEUTICS, INC.	Other Biotechnology & Medical Research	+3.35%	+6.08%	-10.41%	-28.01%	-96.58%	52.84M